Aphranel® Celebrates Its First Anniversary with EU MDR Certification and New Product Launch

Aphranel® Commemorates a Year of Success

On May 20th, 2026, Aphranel® celebrated its first anniversary at the prestigious Waldorf Astoria Shanghai on the Bund. This celebration represents a significant milestone, not just for Aphranel itself, but also for the evolving landscape of regenerative aesthetics. The event highlighted achievements over the past year, including the achievement of EU Medical Device Regulation (MDR) certification, the launch of its innovative Arc™ product, and the impressive delivery of over 150,000 syringes in China alone.

Milestones in Aphranel's Journey

Aphranel’s journey began in May 2025 when it became the first brand in China to receive approval for a calcium hydroxyapatite (CaHA) microsphere injectable facial filler. Fast forward a year, and the brand has cemented its reputation in the market, having expanded its network to cover 28 provinces and 94 cities across China. The company has collaborated with over 620 medical clinics and trained more than 700 physicians, showcasing the trust and acceptance it has gained from both professionals and consumers.

The recent EU MDR certification represents a remarkable achievement for Aphranel®. It has become the first injectable facial filler of Chinese origin to obtain this certification, following an exhaustive 2 years and 7 months of rigorous evaluations that included over 6,381 pages of technical documentation and more than 120 internal regulatory meetings. These efforts were executed in collaboration with BSI, a leading notified body based in the UK.

Launching Arc™: A New Chapter

During the anniversary summit, Aphranel introduced its new flagship product, the Arc™. Described as a revolutionary addition to their line, Arc™ embodies the brand’s philosophy, “The Poetics of Time.” This innovative product focuses on facial contouring within the realm of regenerative aesthetics. The launch of Arc™ signifies a bold step forward in Aphranel’s commitment to merging scientific research with practical applications in aesthetic medicine.

Cutting-Edge Discussions

The anniversary event wasn’t solely about celebrating achievements; it also served as an intellectual gathering where discussions on biomaterial innovation and regenerative medicine took center stage. Leading experts presented new insights into tissue remodeling and aesthetic outcomes, further solidifying Aphranel's role as a thought leader in the industry. Prof. Yuan Tun from the National Engineering Research Center for Biomaterials shared initial findings on the in vivo degradation kinetics and tissue remodeling mechanisms related to Aphranel's CaHA microspheres, enhancing the scientific foundation of their products.

Furthermore, Aphranel introduced “The Norns’ Plan,” a global academic initiative aimed at fostering collaboration and knowledge exchange within the regenerative aesthetic community. This initiative aims to elevate international medical training, collaborative research, and a global mentorship network, establishing Aphranel as a key player in shaping the future of regenerative aesthetics.

Strategic Partnerships and Future Prospects

In addition to its focus on medical innovation, Aphranel announced a strategic partnership with Langjiu Manor, a notable premium spirit producer in China. This collaboration aligns with Aphranel's philosophy of growth over time, bridging aesthetics with cultural and artistic realms.

The immersive artistic experiences at the Waldorf Astoria, inspired by themes of butterflies, architecture, and the passage of time, created a sensory expression of the brand's ethos and reinforced its commitment to creativity and innovation.

Going forward, Aphranel is set to expand its horizons beyond China, planning for significant investments in Europe, Latin America, the Middle East, and Southeast Asia. The founder, Guangming Lin, expressed confidence that the first anniversary is not an end but merely a beginning of new opportunities. Aphranel® is poised to lead the charge in the efficacy and innovation of regenerative aesthetics across the globe.

With an unwavering commitment to scientific research and market-driven solutions, Aphranel® aims to redefine the future of beauty and aesthetics, proving that patience and dedication are key attributes of a brand built for the long term.